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Synergistic activation of soluble guanylate cyclase by YC-1 and 
carbon monoxide: implications for the role of cleavage of the 
iron-histidine bond during activation by nitric oxide 
James R Stone’* and Michael A Marietta* 
Background: Nitric oxide PNO) is used in biology as both an intercellular 
signaling agent and a cytotoxic agent. In signaling, submicromolar quantities of 
*NO stimulate the soluble isoform of guanylate cyclase (sGC) in the receptor 
cell. *NO increases the V,,, of this heterodimeric hemoprotein up to 400-fold 
by interacting with the heme moiety of sGC to form a 5-coordinate complex. 
Carbon monoxide (CO) binds to the heme to form a 6-coordinate complex, but 
only activates the enzyme 5-fold. YC-1 is a recently discovered compound that 
relaxes vascular smooth muscle by stimulating sGC. 
Results: In the presence of YC-1, CO activates sGC to the same specific 
activity as attained with *NO. YC-1 did not affect the NO-stimulated activity. 
The on-rate (ken) and off-rate (k,,) of CO for binding to sGC in the presence of 
YC-1 were determined by stopped-flow spectrophotometry. Neither the k,, nor 
the koif varied from values previously obtained in the absence of YC-I, 
indicating that YC-1 has no effect on the affinity of CO for the heme. In the 
presence of YC-1, the visible spectrum of the sGC-CO complex has a Soret 
peak at 423 nm, indicating the complex is B-coordinate. 
Conclusions: YC-1 has no effect on the affinity of CO for the heme of sGC. In 
the presence of YC-1, maximal activation of sGC by CO is achieved by 
formation of a 6-coordinate complex between CO and the heme indicating that 
cleavage of the Fe-His bond is not required for maximal activation of sGC. 
Introduction 
Living systems have evolved numerous ways to transmit 
information or signals from one cell to another, and one of 
the more unusual ways is the use of the free radical nitric 
oxide (*NO) [1,2]. At low concentrations (below 1 FM), 
*NO is used by cells as a signaling agent. *NO is synthe- 
sized in a cell from the amino acid L-arginine by a 
Ca2+/calmodulin-dependent nitric oxide synthase [3,4]. 
The *NO then freely diffuses to another cell where it acti- 
vates the soluble isoform of guanylate cyclase (sGC). Once 
activated by *NO, sGC synthesizes guanosine 3’,5’-cyclic 
monophosphate (cGMP) from guanosine 5’-triphosphate 
(GTP) [5,6]. The cGMP is, for the most part, retained 
within the second cell where it causes a cascade of bio- 
chemical reactions that results in a physical/functional 
change in the cell. For example, increased cGMP has been 
shown to cause platelet disaggregation, vascular smooth 
muscle relaxation, and intestinal epithelial cell secretion of 
ions and water [5,7,8]. *NO has no effect on the particulate 
isoform of guanylate cyclase (pGC) that is activated by 
small peptide hormones such as atria1 natriuretic factor [6]. 
At concentrations above 1 PM, *NO is employed as a 
cytotoxic agent to kill invading organisms or malignant 
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neoplastic cells. In recent years numerous mechanisms by 
which *NO might act as a cytotoxic agent have been 
described, such as nitrosylation and nitration of proteins 
[9,10], disruption of iron-sulfur centers [ll], and direct 
oxidation of macromolecules via formation of peroxyni- 
trite [12]. All these processes require relatively high con- 
centrations of *NO (~1 FM), however. In contrast, the 
only known way for *NO to act as a signaling agent is by 
activating sGC, giving this enzyme an important role in 
cellular signal transduction. 
sGC has been purified from mammalian sources and 
shown to be a heterodimer, consisting of an a subunit of 
73-88 kDa and a p subunit of 70 kDa [13-161. The two 
subunits of the heterodimer purified from mammalian 
sources so far have been cloned from several mammalian 
cDNA libraries and have been designated as al and pl 
respectively [17-Z 11. Further screening of cDNA libraries 
along with genome studies have revealed sequences for 
other putative sGC isoforms [‘22,23] but the functional sig- 
nificance and native quaternary structure of these isoforms 
remain unclear. The purified enzyme from mammalian 
sources contains bound heme (iron protoporphyrin IX) 
[16,24]. As isolated, the heme is ferrous, but the heme can 
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be oxidized with ferricyanide. Spectral studies have indi- 
cated that the heme is 5coordinate high spin in both the 
ferrous and ferric states and a single histidine is the most 
likely axial ligand [16,25-271. Unlike hemoglobin (Hb) 
and myoglobin (Mb), the S-coordinate ferrous heme in 
sGC has the unusual property of not binding oxygen, even 
at millimolar concentrations [ 161. 
It was first suggested two decades ago [28] that heme 
played a role in the activation of sGC by -NO. Partially 
purified sGC that was not responsive to *NO could be 
activated by *NO if heme was included in the reaction 
mixture. It was proposed later that activation of sGC by 
*NO was a direct result of the formation of a S-coordinate 
nitrosyl-heme complex on the enzyme 1’291 on the basis 
of the observation that the ability of *NO to activate puri- 
fied sGC was dependent on the presence of heme [30]. 
Enzyme containing heme was markedly activated by 
*NO and removal of the heme moiety resulted in the loss 
of the ability of *NO to activate the enzyme. Reconstitu- 
tion of the enzyme with heme partially restored the 
ability of aNO to activate the enzyme. It was also demon- 
strated that purified heme-deficient enzyme could be 
activated by nitrosyl-heme complexes and also by proto- 
porphyrin IX (lacking iron) [31]. This last observation led 
to the speculation that the nitrosyl complex formed on 
sGC was 5coordinate and thus structurally resembled 
protoporphyrin IX. Upon binding of *NO to the heme 
iron, the trans-axial ligand was believed to dissociate from 
the heme. The release of this axial ligand and the subse- 
quent changes in porphyrin structure were postulated to 
mediate a global conformational change in the protein, 
resulting in activation. 
Although the heme in sGC does not bind oxygen, it does 
bind *NO. Electronic absorption, resonance Raman and 
electron paramagnetic resonance spectral studies have 
indicated that the nitrosyl complex is, in fact, 5coordinate 
[16,25,32]. Furthermore, experiments simultaneously mea- 
suring cGMP formation and recording optical spectra have 
demonstrated that the 5coordinate nitrosyl form of the 
enzyme is activated relative to the S-coordinate resting 
state of the enzyme [33]. Also, CO, which forms a 6-coordi- 
nate complex with the heme, only activates purified 
enzyme to l--3% of the levels achieved with *NO [16,34], 
supporting the idea that severing of the Fe-His bond is 
required for full activation of the enzyme. 
YC-1 (3-(5’-hydroxymethyl-2’-furyl)-l-benzylindazole; 
Figure 1) is a recently discovered compound that relaxes 
vascular smooth muscle [35] and inhibits platelet aggrega- 
tion [36-381. These effects were found to be caused by 
elevation of cGMP levels. The target for YC-1 appears to 
be sGC, as YC-1 directly stimulates this enzyme but has 
no effect on pGC [38]. It has been reported recently that a 
much higher cyclase activity can be obtained with sGC in 
Figure 1 
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Chemical structure of 3-(5’-hydroxymethyl-2’-furyl)-l -benzylindazole 
(YC-I). 
the presence of both CO and YC-1 than in the presence of 
either activator individually 1391. Furthermore, it has been 
reported that in the presence of YC-1, much lower con- 
centrations of CO are required to activate sGC than are 
required in the absence of YC-1 [39], which has profound 
implications. For a number of years, it has been proposed 
that, by analogy to *NO generated nitric oxide synthase, 
CO generated by heme oxygenase may serve as an 
endogenous activator of sGC by binding to the heme 
moiety [40,41]. The main evidence contradicting this pro- 
posal is that the level of al pl activation achieved with CO 
is marginal compared to that achieved with *NO and, fur- 
thermore, that nonphysiologically high concentrations of 
CO are required to observe this effect [16,34]. If YC-1 can 
both increase the activation by CO and decrease the con- 
centration of CO required to produce this effect, however, 
then the possibility exists that there is a natural analog of 
YC-1 that may allow CO to function as an endogenous 
activator of sGC. 
Here, it is shown that although YC-1 is synergistic with 
CO in activating sGC, YC-1 has no effect on the on-rate 
(k,,) or off-rate (k,,) of CO for binding to the heme. Addi- 
tionally, it is demonstrated that in the presence of YC-1 
CO forms a 6-coordinate complex with the heme and acti- 
vates the enzyme to the same extent as does *NO. On the 
basis of these results, the requirement for cleavage of the 
Fe-His bond to achieve full activation of sGC is called 
into question. 
Results 
Activation of sGC by YC-1 and CO 
YC-1 (100 FM) or CO (1 atm, 800 PM) added alone only 
activates sGC S-fold (Table l), whereas *NO (OS%, 8 l.tM) 
activates the enzyme 178-fold. In the presence of both CO 
and YC-1, however, the specific activity was similar to that 
achieved with *NO, indicating a synergism between CO 
and YC-1 for activating the enzyme. The presence of 
YC-1 had no effect on the activity of enzyme activated 
with *NO. All activities were linear over 10 minutes. 
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Table 1 
Activation of sGC with *NO, CO and X-1. 
YC-I Specific activity Activation 
Gas in headspace (100 VW (nmole min-l mg-l) (x-fold) 
Argon 98i7 
Argon + 532 f 25 5.4 i: 0.5 
Carbon monoxide - 471 i48 4.8 2 0.6 
Carbon monoxide + 15,800 I 1,200 161 f17 
0.5% *NO in argon - 17,400 F 400 178113 
0.5% *NO in argon + 15,400 + 600 157f13 
All errors represent one standard deviation. The errors for the 
specific activities correspond to the errors in the slopes from the 
linear regressions of the plots of product versus time. The errors in 
the activations were derived from propagation of the errors in the 
specific activities. 
Stopped-flow kinetics 
Representative traces for the binding of CO to sGC are 
shown in Figure 2. The total absorbance change was not 
the same for the different concentrations of CO because 
the binding site was not saturated. Each trace in Figure 2 
has a single exponential fit superimposed on the data. 
From the single exponential fits of the data, pseudo first- 
order (observed) rate constants (kobs) were obtained. A 
plot of these constants against the concentration of CO is 
shown in Figure 3. The plot was linear, consistent with a 
simple one-step binding mechanism. The slope of the line 
is the k,, for CO [(3.63 f 0.15) x lo4 M-ls-t], and the 
y intercept is the k,, (3.4 f 0.5 s-l). The k,, divided by 
the k,, (94 + 14 FM) is a calculated value for the K, for the 
binding process. These values are in good agreement with 
the values determined previously in the absence of YC-1 
(Table Z), demonstrating that YC-1 has no effect on the 
affinity of CO for binding to the heme of sGC. 
Measurement of the Kd of CO 
Representative spectra taken in the stopped-flow spec- 
trophotometer are shown in Figure 4. In the presence of 
100 PM YC-1 and the absence of CO, the Soret peak is 
located at 431 nm, indicating a Scoordinate heme complex 
with histidine as the axial ligand as determined previously 
[16,25]. Thus, YC-I partially activates the enzyme without 
altering the heme coordination. In the presence of 
0.62 mM CO and IO0 FM YC-1, the Soret peak shifts to 
423 nm, indicating a 6coordinate CO complex [16,25,42]. 
Using values generated from difference spectra, a plot of 
the MAbs(423440) versus the CO concentration is shown 
in Figure 5. Fitting the data with a typical saturation func- 
tion, AAAbs = {AAAbs(max) x [CO]}/{K, + [CO]}, yields a 
K, of 73 f 18 FM for the binding of CO to the heme of 
sGC. This value is in good agreement with the value 
obtained from the rate constants and with the spectrally 
derived equilibrium constant obtained previously in the 
absence of YC-1 (Table 2). 
Fiaure 2 
Stopped-flow monitoring of the binding of CO to sGC in the presence 
of YC-1. Original data (solid line), single exponential fit (dashed line). 
For all concentrations of CO, the data and the fit are essentially 
superimposable. Experimental conditions were as described in the 
Materials and methods section. The concentrations of CO shown are 
the final concentrations after mixing. 
Discussion 
The molecular details of *NO activation of sGC remain 
largely unanswered and are integral to the complete 
understanding of *NO signal transduction. Of great 
importance is the understanding of the unique properties 
of the heme moiety of the receptor that allow specific 
interaction with *NO in the presence of much higher con- 
centrations of 0,. Perhaps even more important is the 
mechanism that leads to dissociation of *NO from the 
Figure 3 
k,, = (3.63 + 0.15) x 104 M-‘s-1 
25 
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CO concentration (mM) chemistry & siology 
Plot of k ohs against CO concentration. The pseudo first-order rate 
constants (k,,,) obtained from the single exponential fits of the 
stopped-flow data were plotted against the final concentrations of CO. 
The k,, is obtained from the slope, the k,, from the y intercept and the 
Kd from k,, / k,,. 
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Table 2 
Comparison of kinetic and equilibrium binding constants for CO. 
YC-1 (100 FM) k,, (M-‘s-l) koff (s-‘) K, (calc’d, PM)* K, (meas., FM)+ 
Absent* (3.58 i 0.15) x 1 O4 3.5 rt 0.5 98f15 97 + 9 
Present (3.63 r.h 0.15) x 104 3.4 k 0.5 94+14 73+18 
All errors represent one standard deviation. The errors for k,, and k,, 
correspond to the errors in the slopes and y intercepts respectively 
from the linear regressions of the plots of kobs against CO 
concentration. The errors in K, (calc’d) were derived from propagation 
heme, thereby returning the enzyme to the resting state. 
As *NO typically dissociates very slowly from ferrous heme 
complexes, unusual structural features must exist in the 
heme-binding site of sGC to allow the rapid dissociation of 
*NO required for cellular signaling. 
The current working model of sGC activation includes a 
resting state of the enzyme that has low basal activity and 
a high-spin ferrous heme with a histidine residue as the 
axial ligand [16,25]. Our most recent studies with the 
native enzyme (unpublished observations, P.E. Brandish, 
S. Kim, J.R.S. and M.A.M.) and with an amino-terminal 
fragment of the B subunit [43,44] are consistent with a 
heme to heterodimer ratio of 1:l. Mutagenesis studies 
have implicated His105 in the B subunit as the likely 
heme ligand for the bovine lung isoform [43-45]. Upon 
*NO binding to the heme, the activity of sGC increases 
dramatically (up to 400-fold) and the heme is converted to 
Figure 4 
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Electronic absorption spectra of sGC. Spectra were recorded on the 
stopped-flow spectrophotometer after each kinetics measurement. 
Spectra in the presence of 100 uM YC-1 either in the absence (dotted 
line) or presence (solid line) of 620 uM CO are shown. 
of the errors in the k,, and k,,. The errors in K, (meas.) correspond to 
the error derived in fitting the plot in Figure 5 with a standard 
saturation function. *Calculated from k,,/k,,. +Measured directly from 
spectra. *Previously reported [34]. 
a S-coordinate complex with *NO bound to the distal side 
of the heme [27,33]. After treatment with *NO, the 
Fe-His bond is broken, a finding that has been confirmed 
using electronic, electron paramagnetic and resonance 
Raman spectroscopies [25,32]. It has been speculated, 
moreover, that *NO binding leads to a conformational 
change with a subsequent increase in activity, perhaps by 
rearrangement of essential active-site residues. 
There are two major sources of movement in the regula- 
tory portion of the protein brought about by *NO binding 
to the heme in sGC. First, in the porphyrin macrocycle, 
the porphyrin is likely to be puckered towards the distal 
histidine ligand in the resting state and puckered in the 
opposite way in the *NO complex. The significant move- 
ment of the porphyrin ring upon *NO binding could, in 
principle, provide the driving force for a global conforma- 
tional change and the increase in catalytic activity. We 
have shown previously that CO is a weak activator of the 
enzyme (see below); furthermore, we have shown that the 
Figure 5 
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CO concentration (mM) Chemistry & eiology 
Plot of MAbs(423-440) against CO concentration. The 
AAAbs(423-440) obtained from difference spectra were plotted 
against the final concentration of CO. The data were fit with a standard 
saturation function, AAAbs = (AAAbs(max) x [COIII{Kd + [COI) to 
determine the K,. 
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CO-sGC complex is 6-coordinate [2.5,34]. This complex 
would probably have a nearly planar heme with little 
puckering, resulting in a geometry in between that of the 
activated and unactivated enzyme. The second source of 
movement in the regulatory portion of the protein 
involves the breakage of the Fe-His bond and the subse- 
quent movement of the protein backbone. The increase in 
catalytic activity coincident with *NO binding almost cer- 
tainly involves either one or both of these movements, but 
there is no direct evidence to quantitatively support either 
mechanism of activation. 
Our results with YC-1 shed some light on the mechanism 
of sGC activation. The results reported here clearly show 
that treatment of sGC with YC-1 and CO act synergisti- 
cally, leading to an increase in activation that is essentially 
the same as that observed with *NO alone (Table 1). Sig- 
nificantly, as shown by our spectral results, the activation 
with YC-1 and CO occurs without breakage of the Fe-His 
bond (Figure 4). This result shows conclusively that full 
activation can be obtained without the cleavage of the 
Fe-His bond and, thus, without any movement of the 
protein backbone requiring the cleavage of this bond. In 
agreement with our results, Koesling and colleagues [39] 
have recently reported that YC-1 and CO act synergisti- 
cally to activate sGC. Additionally, we both observe a 
small increase in activity with YC-1 alone (5.4-fold, 
Table 1; l&fold [39]), similar to that seen with CO alone. 
They also reported that lower concentrations of CO were 
required to activate the enzyme when YC-1 was present. 
Analysis of their data reveals an EC,, for CO of -37 FM in 
the presence of YC-1; the corresponding EC,, without 
YC-1 cannot be estimated from the data in the paper [39]. 
The value of 37 yM obtained with YC-1, however, is in 
excellent agreement with an analogous value determined 
by us previously in the absence of YC-1 (aK, = 36 + 8 PM) 
[34], indicating that YC-1 does not affect the EC,, of CO 
for activating the enzyme. In a very recent follow-up study 
by the same group 1461 it was concluded that YC-1 
decreased the k,, of CO from the heme, thus increasing 
the affinity of CO for the heme. In that study, occupation 
of the heme site with CO was assessed by enzyme activity 
measurements and not spectrally (as was done here), so 
multiple interpretations of the data are possible. 
Under -NO-saturating conditions, Friebe et al. [39] 
observed an increase in the *NO-stimulated activity with 
the addition of YC-1, whereas we did not (Table 1). There 
were differences in enzyme preparation and experimental 
protocols, however, so it is not clear that this difference in 
our results is significant. They did show that YC-1 
enhances the activation of the enzyme achieved with sub- 
saturating concentrations of a *NO donor. Studies on 
organs measuring vascular smooth muscle relaxation also 
observed this synergism when low *NO-donor concentra- 
tions were used [35]. A possible explanation for the result 
is that YC-1 increases the affinity of *NO for the heme, 
even though this was not the case for CO. The rate limit- 
ing step in the dissociation of *NO from the heme of sGC 
has been proposed to be the reassociation of the axial his- 
tidy1 ligand to the heme 1331, a step that does not occur 
when CO dissociates from the enzyme. YC-1 may there- 
fore increase the affinity of *NO for the heme by decreas- 
ing the k,, of *NO from the heme by decreasing the rate 
of the iron-histidine re-ligation. 
From the work reported here we know the effect of YC-1 
on the kinetic constants of association and dissociation and 
on the equilibrium constant with respect to CO. Our 
results also clearly show that the mechanism of YC-1 action 
does not involve altering either the k,, or k,, for CO and, 
hence, has no effect on the equilibrium constant (Table 2). 
We had previously determined the k,, for CO and found it 
to be significantly faster when compared to other ferrous- 
heme-CO complexes with a histidyl axial ligand, such as 
hemoglobin and myoglobin (341. As YC-1 and CO act syn- 
ergistically to activate sGC, one possibility was that YC-1 
also enhanced the affinity of CO for the heme by decreas- 
ing the k,, but clearly this is not the case. 
How does YC-1 exert the observed effects on sGC? The 
answer to this question will come only after more studies 
with YC-1, such as detailed spectroscopy and determina- 
tion of the YC-l-binding site. It is tempting to draw an 
analogy between the homologous catalytic domains of the 
adenylate cyclases and their activation by forskolin and 
the activation of sGC by YC-1. Two recent crystal struc- 
tures, a type IICZ homodimer by Hurley and colleagues 
[47] and a type VClIIC2 heterodimer by Sprang and col- 
leagues [48], have both shed light on how forskolin func- 
tions. It is clear from the structures, as well as from 
biochemical results generated by Gilman and colleagues 
[49], that forskolin acts to stabilize the dimer interface. As 
the active site involves residues from both subunits, it is 
clear how forskolin could act to increase activity. Forskolin 
only increases the apparent affinity of VCl for IICZ from 
210 PM to -1 PM, however, which is not enough to 
account for the level of activation observed with forskolin, 
and it has been suggested that forskolin also acts by alter- 
ing the conformation of the protein at the active site. 
Whether there is a natural analog of forskolin is not known. 
Regulation of adenylate cyclase in &vo is essential for the 
physiological processes controlled by this enzyme so the 
implications of a natural counterpart of forskolin are signif- 
icant. The same significance with respect to sGC is true 
for sGC and a natural analog of YC-1. Specifically, it has 
been proposed that CO derived from heme oxygenase 
functions as a mediator of intercellular communication by 
activation of sGC [40,41] on the basis of the ability of high 
concentrations of CO to inhibit platelet aggregation and to 
relax vascular smooth muscle through an increase in cGMP 
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[50,51]. The difficulty with this hypothesis is that the con- 
centrations of CO used were high and well outside of what 
would be expected to be generated physiologically. Fur- 
thermore, the resulting activation of sGC is only 5fold 
with the purified bovine lung form of the enzyme [16]. 
Although it is possible that a unique CO-sensitive isoform 
exists, such an isoform has never been isolated. The 
results with YC-1 show that a high CO-stimulated activity 
can be obtained, although YC-1 did not alter the K, for 
CO. A natural analog of YC-1 might both increase stimula- 
tion by CO and lower the K, for CO; the existence of such 
an analog would support the CO-signaling hypothesis. 
Significance 
The soluble isoform of guanylate cyclase (sGC) is the 
only definitively characterized receptor for the intercel- 
lular signaling agent nitric oxide (*NO). The native 
enzyme is a heterodimer composed of a and p subunits. 
*NO is known to interact with a ferrous protoporphyrin 
IX heme on sGC, leading to up to a 400-fold increase in 
activity. The previously accepted model of activation, on 
the basis of spectroscopic studies, showed that the 
resting enzyme is a Scoordinate complex with axial liga- 
tion to a histidine residue. Upon *NO binding the heme 
is converted to a S-coordinate complex with *NO bound 
in the distal position and the Fe-His bond broken. Con- 
formational changes speculated to occur with the forma- 
tion of the *NO complex are thought to be involved in 
the activation of sGC. CO is a weak (approximately 
S-fold) activator of the enzyme; the resulting CO-sGC 
complex was determined to be 6-coordinate with the 
Fe-His bond intact and CO bound on the distal side of 
the heme. The present studies with 3-(S’-hydroxymethyl- 
2’-fury&1-benzylindazole (YC-1) and CO show that 
sGC can be fully activated without severing the Fe-His 
bond. These results require a new model to explain acti- 
vation of sGC and, furthermore, suggest that a natural 
analog of YC-1 could induce dramatic changes in the 
activity and biological action of sGC. 
Materials and methods 
Materials 
CO (99%) was obtained from Liquid Carbonic Specialty Gases 
(Chicago, IL). *NO (99,00/o) was obtained from Matheson. sGC was 
purified from bovine lung using a scaled-up version (data not shown) of 
a previously reported procedure [27]. YC-1 was a generous gift from 
Professor Che-Ming Teng, National Taiwan University. Stock solutions 
were prepared in DMSO, and the YC-1 concentration was determined 
gravimetrically. All other materials unless otherwise stated were 
obtained from Sigma. 
Stopped-flow kinetics 
sGC (1.5 uM heme) in 25 mM TEA, 5 mM dithiothreitol (DTT), 50 mM 
NaCI, 100 PM YC-I, 1% DMSO, pH 7.4, under air was rapidly mixed 
with an equal volume of the same buffer containing varying concentra- 
tions of CO. The CO solutions were prepared by bubbling buffer for 30 
min with a CO/N, mixture. The concentration of CO in solution was 
determined using a solubility of 0.003479g of CO per 1OOg H,O at 
10°C (assuming no effect of added solutes) when the partial pressure 
of CO in the headspace is 760 mm Hg [52]. The gas mixtures were 
prepared using a 150 mm gas proportioner equipped with high-resolu- 
tion valves (Air Products). Data were acquired on a HI-TECH Scientific 
SF-61 stopped-flow spectrophotometer controlled by KISS software 
(Kinetic Instruments, Ann Arbor, MI) at 10°C. The binding of CO to the 
heme was monitored as an increase in the absorbance at 423 nm. For 
each CO concentration, the experiment was performed in triplicate, 
and the resulting traces were averaged. The final traces were then fit to 
a single exponential using KISS software. 
Measurement of the Kd of CO for binding to the heme 
Upon completion of each stopped-flow experiment, a spectrum was 
obtained of the equilibrium mixture. For each concentration of CO, the 
final spectrum had subtracted from it a spectrum of sGC mixed with 
buffer lacking CO. These difference spectra were used to determine the 
AAbs(440), AAbs(423), and subsequently the AAAbs(423-440). A plot 
of the AAAbs(423-440) versus the CO concentration was fit with a 
typical saturation function, AAAbs = (AAAbs(max) x [COI)/{K, f [CO]}, 
to determine the Kd of CO for binding to the heme. 
Activation of purified sGC with *NO, CO and YC- 1 
*NO was purified of other nitrogen oxides by bubbling through saturated 
KOH. Buffer containing 50 mM TEA pH 7.4, 2 mM DTT, 4.5 mM MgCI,, 
1.5 mM GTP, and 1% DMSO, with or without 100 uM YC-1 was placed 
in a gas-tight vial under 1 atmosphere of the appropriate gas and warmed 
to 37°C. Previously 100 PM YC-1 was found to be saturating (or near- 
saturating) for the activation of sGC [39]. The reaction was initiated by 
the injection of 4 ul of sGC with a gas-tight syringe to give a final reaction 
volume of 1 .O ml with an enzyme concentration of 0.80 uglml. At time 
intervals (0, 2, 5, 7, and 10 min), 100 ul aliquots were removed with a 
gas-tight syringe and quenched with 400 pl of 125 mM Zn(CH,COO), 
and 500 1.11 of 125 mM Na,CO,. The amount of cGMP generated was 
then quantitated via radioimmunoassay (Amersham). 
Protein determination 
Protein concentrations were determined using the Bradford microassay 
(Bio-Rad) using BSA as the standard. 
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